Implantable devices for drug delivery with reduced burst release

a technology of implantable devices and drug delivery, which is applied in the direction of drug compositions, peptide/protein ingredients, other domestic articles, etc., can solve the problems of impaired cognitive function, inconvenient or difficult compliance with extended dosing regimens, and many problems, so as to improve the control and tuning of the release rate, the effect of reducing the burst releas
US20210007973A1Inactive Publication Date: 2021-01-14FEDSON INC
0 Cites 8 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
FEDSON INC
Publication Date
2021-01-14
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides implantable drug delivery devices comprising a core comprising a polymer (or polymer blend) and one or more drugs or pharmaceutical substances, and an outer shell comprising a polymer (or polymer blend) and one or more porogen materials. The invention reduces burst release of drug. Pharmaceuticals such as triiodothyronine (T3) or ropinirole can be delivered by the devices.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This patent application claims priority benefit of U.S. Provisional Patent Application No. 62 / 404,643 filed Oct. 5, 2016. The entire contents of that application are hereby incorporated by reference herein.TECHNICAL FIELD

[0002] The invention provides devices which can be implanted into a patient for release of pharmaceutical substances, such as triiodothyronine, over long periods of time, with reduced, minimal, or no burst release.BACKGROUND OF THE INVENTION

[0003] Many patients require long-term, regular dosing with drugs or pharmaceutical substances. Effective treatment often necessitates the ingestion of one or more tablets per day for extended periods of time. For example, patients who undergo thyroidectomy, a common treatment for thyroid cancer, must take oral thyroxine tablets for the rest of their lifetime. Typically, patients take levothyroxine (T4), which is converted in vivo into triiodothyronine (T3). Both T4 and T3 regulate a wid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More